Eli Lilly and Company and MiNA Therapeutics Ltd have announced a global research collaboration to develop novel drug candidates using MiNA’s proprietary small activating RNA (saRNA) technology platform.
London-based MiNA has been researching saRNA – ‘an entirely new class of medicines with potential to offer transformational benefits to patients across a wide range of diseases’ – with a focus on cancer and other severe metabolic and genetic diseases. saRNA is designed to restore cells’ natural production of proteins: with saRNA promoting production of mRNA and consequently the required protein. Its most advanced program is in a Phase 1/2 trial.
In the partnership with Lilly, MiNA will use its platform to research up to five areas selected by Lilly in its key therapeutic focus areas. Lilly will take on responsibility for preclinical and clinical development of candidates and retain exclusive commercialization rights for any products resulting
Mangini Pleads Guilty In New York | Standardbred Canada
standardbredcanada.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from standardbredcanada.ca Daily Mail and Mail on Sunday newspapers.
Scott Mangini, Online Peddler Of Performance Enhancing Drugs, Pleads Guilty In Federal Court - Horse Racing News
paulickreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from paulickreport.com Daily Mail and Mail on Sunday newspapers.